SCHEMBL2232804

SCHEMBL2232804

CC(C)c1ccc(CCOc2ccc(CN3CCN(C(=O)O)CC3)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 2/20 0.57
HTT P42858 1/20 0.57
FAAH O00519 4/20 0.54
PPARG P37231 1/20 0.50
PPARD Q03181 1/20 0.50
PPARA Q07869 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
PKM P14618 2/20 0.48
POLB P06746 1/20 0.48
GPR183 P32249 1/20 0.47
S1PR1 P21453 1/20 0.47
S1PR5 Q9H228 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231731 1.00 HRH3 (0.58) HRH3SMN1; SMN2ALDH1A1HTTFAAH
SCHEMBL13582370 0.96 HRH3 (0.60) HRH3SMN1; SMN2ALDH1A1HTTFAAH
SCHEMBL2233177 0.94 HRH3 (0.57) HRH3SMN1; SMN2ALDH1A1HTTFAAH
SCHEMBL2235879 0.88 FAAH (0.59) HRH3SMN1; SMN2ALDH1A1FAAHKDM4E
SCHEMBL2232489 0.88 HRH3 (0.74) HRH3SMN1; SMN2ALDH1A1HTTFAAH
SCHEMBL2232545 0.88 HRH3 (0.55) HRH3SMN1; SMN2ALDH1A1FAAHMEN1
SCHEMBL2301871 0.88 SMN1; SMN2 (0.54) HRH3SMN1; SMN2ALDH1A1HTTFAAH
SCHEMBL2233436 0.87 SMN1; SMN2 (0.57) HRH3SMN1; SMN2ALDH1A1FAAHKDM4E
SCHEMBL13581848 0.87 NPC1 (0.51) HRH3SMN1; SMN2FAAHKDM4ELMNA
SCHEMBL2232206 0.87 POLB (0.57) HRH3SMN1; SMN2ALDH1A1HTTFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
EP-2528897-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS Otsuka Pharmaceutical Co., Ltd. (JP) 2012-12-05 EP disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
WO-2011093524-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 HRH3 663/4885SMN1; SMN2 4081/4885ALDH1A1 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.